EKF Diagnostics Holdings plc provided earnings guidance for the second half of 2024 and full year 2024. Revenues remain in-line with management expectations and, as expected, will show a lower performance year-on-year due to the termination of operations and non-core, low margin products (which are being removed from the portfolio) contributing to first half of 2023 comparators. TheLife Sciences division's fermentation business performed particularly well in the first half, recording sales growth of 41% year-on-year.

The company expects this improvement in performance to continue in second half of 2024 and remains confident that full year results will be in-line with market expectations.